PA
KRON

Perceptive Advisors’s Kronos Bio KRON Stock Holding History

Perceptive Advisors’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,752,745
Closed -$2.19M – 118
2023
Q4 		$2.19M Hold
1,752,745
– – 0.05% 87
2023
Q3 		$2.28M Hold
1,752,745
– – 0.08% 82
2023
Q2 		$3.01M Hold
1,752,745
– – 0.09% 79
2023
Q1 		$2.56M Hold
1,752,745
– – 0.08% 87
2022
Q4 		$2.84M Sell
1,752,745
-403,406
-19% -$929K 0.08% 81
2022
Q3 		$7.22M Sell
2,156,151
-264,991
-11% -$1.2M 0.21% 71
2022
Q2 		$8.81M Hold
2,421,142
– – 0.28% 65
2022
Q1 		$17.5M Hold
2,421,142
– – 0.35% 63
2021
Q4 		$32.9M Hold
2,421,142
– – 0.51% 51
2021
Q3 		$50.7M Sell
2,421,142
-106,910
-4% -$2.3M 0.74% 32
2021
Q2 		$60.5M Sell
2,528,052
-252,045
-9% -$6.38M 0.79% 37
2021
Q1 		$79.7M Hold
2,780,097
– – 1.01% 27
2020
Q4 		$83M Buy
+2,780,097
New +$87.2M 0.89% 31

Other funds holding KRON

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Perceptive Advisors's KRON Position: Q1 2024 in Review

Perceptive Advisors sold out of Kronos Bio (KRON) in Q1 2024, closing a stake of 1,752,745 shares — an estimated $2.19M sold.

Perceptive Advisors first reported a position in KRON in Q4 2020 and held it in 13 quarters. The position peaked at $83M in Q4 2020. 58 funds tracked by Wall St. Rank hold KRON as of Q1 2024.

  • Perceptive Advisors reported no remaining Kronos Bio position as of Q1 2024 after selling out during the quarter.
  • Perceptive Advisors sold 1,752,745 Kronos Bio shares in Q1 2024, an estimated $2.19M.
  • Perceptive Advisors first reported a position in Kronos Bio in Q4 2020 and held it in 13 quarters.
  • Perceptive Advisors's Kronos Bio position peaked at $83M in Q4 2020.
  • 58 funds tracked by Wall St. Rank held Kronos Bio as of Q1 2024.

Based on Perceptive Advisors's 13F filing for Q1 2024, filed 15 May 2024.